Journal of Clinical Oncology
Articles in this Issue
Biomarkertesting in metastatic colorectal cancer (mCRC): 2015-2024 trends in the United States (US) community oncology setting.
e15573 Background: The availability of biomarker-targeted therapies has changed the treatment landscape for mCRC. Starting in 2009, cetuximab was approved...
Treatment preferences between survival and quality of life and their association with clinical outcomes in older adults with advanced cancer.
11013 Background: Preference-concordant care improves quality of life (QoL) and reduces healthcare utilization. However, limited research exists on how pr...
Immune checkpoint inhibitor use and health care utilization in an academic center: A retrospective cohort analysis.
e23171 Background: Immune checkpoint inhibitors (ICIs) are widely used to treat various cancer types. Despite their clinical benefits, the morbidity and m...
Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study).
TPS8122 Background: Pleural mesothelioma (PM) is a rare cancer related to asbestos exposure, marked by complex histopathological diagnosis and dismal prog...
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer.
e20660 Background: Resistance to EGFR- tyrosine-kinase inhibitors (TKI), both intrinsic and acquired, presents a major challenge in EGFR mutant non-small-...
Performance of a blood-based screening test for the early detection of colorectal cancer.
e15627 Background: While the clinical benefit of highly sensitive screening tools for colorectal cancer (CRC) has been established, adherence rates remain...
Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, phase 2, cohort-1 trial.
8640 Background: Vabametkib (ABN401) is a tyrosine kinase inhibitor (TKI) targeting MET. It has previously demonstrated preliminary efficacy in patients(p...
Barriers, facilitators, and practice patterns for next-generation sequencing testing use for non-small cell lung cancer patients.
e23246 Background: Next-generation sequencing (NGS) testing is used to identify driver mutations to guide selection of therapy in early-stage and metastat...
Second-line ASKB589 plus chemotherapy for advanced gastric or gastroesophageal cancers: Results from cohort 5 of a phase I/II study.
4044 Background: ASKB589 is a humanized monoclonal antibody with enhanced affinity for CLDN18.2 and increased ADCC activity. It has shown favorable safety...
Quantitative IHC and AI based evaluation of HER2 low and ultra-low expression in breast cancer specimens.
e13603 Background: Recent advancements in antibody drug conjugate therapies have significantly broadened treatment options for a substantial subgroup of b...
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
9517 Background: OBX-115 TIL are engineered to express mbIL15 regulated by the FDA-approved small-molecule drug acetazolamide (ACZ), abrogating the need f...
Survival outcomes of advanced ovarian cancer treated with neoadjuvant chemotherapy versus primary cytoreductive surgery using a quality-assured decision-making approach.
5577 Background: Neoadjuvant chemotherapy (NACT) is recommended for advanced ovarian cancer patients with a low likelihood of achieving complete cytoreduc...
One-year impact of a large-scale pilot multimodal personalized early cancer detection and prevention program for individuals at high risk of cancers.
10543 Background: The Interception program (IP) is a unique initiative aiming to assess the value of a dedicated personalized care pathway for individuals...
In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.
3121 Background: ASXL1 (Additional sex combs-like 1) gene encodes ASXL1 protein thought to disrupt chromatin, enhancing transcription of certain genes whi...
The impact of prostate cancer on outcomes of patients hospitalized with acute myocardial injury: A national representative sample.
e17165 Background: Prostate cancer has seen improved survival rates due to advancements in diagnosis and treatment. However, these gains have come with ne...
Exploring the impact of SBRT on dendritic cells in the tumor microenvironment of triple-negative breast cancer: Insights from combination with thymosin α1.
e13128 Background: Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, which limits treatm...
Trends of gastrointestinal secondary primary malignancy in chronic lymphocytic leukemia patients from 2000-2021: Surveillance, Epidemiology, and End Results (SEER) database.
e15698 Background: Chronic lymphocytic leukemia (CLL), the most common leukemia in the U.S. and among elderly populations, has an incidence of 4.9 per 100...
A systematic review of CAR T-cell therapy in lung cancer: Move forward or move on?
e20561 Background: Chimeric antigen receptor (CAR) technology has advanced cancer treatment, but predominantly hematopoietic malignancies. CAR T progress...
Initial results from a phase I study of the SHP2 inhibitor GH21 as monotherapy in patients with advanced solid tumors.
e15140 Background: GH21 is a selective, orally bioavailable allosteric inhibitor of SHP2, an oncogenic phosphatase that plays a crucial role in the RAS-MA...
Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from the RCTS trial.
4059 Background: Anti-PD1 antibody has significantly improved survival in patients with HER2-overexpressing and PD-L1 combined positive score (CPS) ≥1 GC/...
A randomized controlled trial of high-fidelity simulation versus mentoring training for residents: ACACIAS 2.
TPS9046 Background: In medical oncology, the "know-how-to-be" aspect of training is crucial but often underemphasized in resident education. Typically, re...
15-year survivorship in patients with metastatic gastrointestinal stromal tumors.
11525 Background: Prior studies of metastatic gastrointestinal stromal tumors (mGIST) have largely focused on 5-year survival when evaluating long-term ou...
Decoding immunotherapy responders in hepatocellular carcinoma patients with stable disease: Multi-omics insights and machine learning model development.
e16188 Background: Over 40% of hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs) manifest stable disease (SD). This...
Role of transcription factor SOX30 in triple-negative breast cancer metastasis and tumor immune microenvironment through the TNF/TNFR2-NF-κB-CCL20/CCR6 axis.
e13037 Background: Triple-negative breast cancer (TNBC) is more aggressive and more difficult to treat than other types of breast cancer due to tumor meta...
Pretreatment insights into primary sarcoma tissues using a novel approach of ex-vivo functional profiling to quantify cytotoxic and anti-proliferative effects of chemo and targeted therapies.
e23529 Background: Sarcoma treatment relies on doxorubicin- or ifosfamide-based regimens, or combinations like gemcitabine and docetaxel. While genomic te...